{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:49:31Z","timestamp":1789735771131,"version":"4.0.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070883, 82273982"],"award-info":[{"award-number":["82070883, 82273982"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Non-alcoholic steatohepatitis (NASH) is the most prevalent chronic liver condition globally, with potential progression to cirrhosis, and even hepatocellular carcinoma (HCC). The increasing prevalence of NASH underscores the urgent need for advanced diagnostic and therapeutic strategies. Despite its widespread impact, effective treatments to prevent the progression of NASH remain elusive, highlighting the critical importance of innovative molecular techniques in both the diagnosis and management of this disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Six microarray datasets available in GEO were used to perform Robust Rank Aggregation (RRA) to identify differentially expressed genes (DEGs).We identified 62 robust upregulated genes and 24 robust downregulated genes. These genes were undergone Gene Ontology enrichment analysis and further examination for expression correlation with NAS score. Molecular subtypes were generated using \u201cConsensusClusterPlus\u201d on identified genes, which were further assessed for tumor stage relevance, expression differences in adjacent and tumor tissues, and impact on survival in TCGA liver cancer patients. Single-cell analysis was then used to explore the genes across different cell types and subgroups as well as cell-type interactions. The clinical utility of predicted core genes was highlighted through decision curve analysis, with emphasis on HCC prognosis. The GDSC database was used to evaluate the relationship between the predicted core genes and drug sensitivity, while the TIDE database was used to evaluate their relationship with immunotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four core genes, <jats:italic>TREM2<\/jats:italic>, <jats:italic>GDF15<\/jats:italic>, <jats:italic>TTC39A<\/jats:italic>, and <jats:italic>ANXA2<\/jats:italic>, were identified as key to influencing HCC prognosis and therapy responsiveness, especially immune treatment efficacy in NASH-associated HCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The core genes may act as critical biomarkers driving the progression of NASH to HCC. They are potential novel targets for the diagnosis and treatment of NASH progression, offering innovative perspectives for its clinical management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1502263","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T05:10:43Z","timestamp":1733289043000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Biomarkers and potential therapeutic targets driving progression of non-alcoholic steatohepatitis to hepatocellular carcinoma predicted through transcriptomic analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Hui","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(23)60469-8","article-title":"Sbc (Sanhuang Xiexin tang combined with Baihu tang plus Cangzhu) alleviates nafld by enhancing mitochondrial biogenesis and ameliorating inflammation in obese patients and mice","volume":"21","author":"Ren","year":"2023","journal-title":"Chin J Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"20181115","DOI":"10.3390\/cancers10110447","article-title":"Lipid metabolic reprogramming in hepatocellular carcinoma","volume":"10","author":"Nakagawa","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(23)60403-0","article-title":"Therapeutic potential of alkaloid extract from codonopsis radix in alleviating hepatic lipid accumulation: insights into mitochondrial energy metabolism and endoplasmic reticulum stress regulation in nafld mice","volume":"21","author":"Fan","year":"2023","journal-title":"Chin J Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies","volume":"28","author":"Sunny","year":"2017","journal-title":"Trends Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in nash drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-5364(24)60690-4","article-title":"Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies","volume":"22","author":"Chen","year":"2024","journal-title":"Chin J Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0145-7","article-title":"From nash to hcc: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.007","article-title":"Nafld-driven hcc: safety and efficacy of current and emerging treatment options","volume":"76","author":"Foerster","year":"2022","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155179","article-title":"Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease","volume":"130","author":"Baars","year":"2022","journal-title":"Metabolism"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk1866","article-title":"Hepatic danger signaling triggers TREM2+macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation","volume":"16","author":"Linkang","year":"2024","journal-title":"Sci Transl Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.cmet.2022.07.010","article-title":"Neuregulin 4 suppresses NASH-HCC development by restraining tumor-prone liver microenvironment","volume":"34","author":"Peng","year":"2022","journal-title":"Cell Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23594","article-title":"Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection","volume":"51","author":"Starley","year":"2010","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic cd8+ T cells and nkt cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0","article-title":"Nash limits anti-tumour surveillance in immunotherapy-treated hcc","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature24302","article-title":"Inflammation-induced iga+ Cells dismantle anti-liver cancer immunity","volume":"551","author":"Shalapour","year":"2017","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature10599","article-title":"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development","volume":"479","author":"Kang","year":"2011","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature16969","article-title":"Nafld causes selective cd4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pby005","article-title":"New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: A balancing act between immunosuppression and immunosurveillance","volume":"1","author":"Karin","year":"2018","journal-title":"Precis Clin Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (Keynote-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (Checkmate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human nafld: disentangling microbial signatures from metabolic disorders","volume":"17","author":"Aron-Wisnewsky","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr709","article-title":"Robust rank aggregation for gene list integration and meta-analysis","volume":"28","author":"Kolde","year":"2012","journal-title":"Bioinformatics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"Clusterprofiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.12.002","article-title":"Hydrodynamic transfection for generation of novel mouse models for liver cancer research","volume":"184","author":"Chen","year":"2014","journal-title":"Am J Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00837-1","article-title":"The biology of trem receptors","volume":"23","author":"Colonna","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.646523","article-title":"Systematic pan-cancer analysis identifies trem2 as an immunological and prognostic biomarker","volume":"12","author":"Cheng","year":"2021","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41392-020-00356-8","article-title":"Trem2 marks tumor-associated macrophages","volume":"5","author":"Nakamura","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091315","article-title":"Trem2 acts as a tumor suppressor in colorectal carcinoma through wnt1\/beta-catenin and erk signaling","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.cell.2017.04.014","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0115-x","article-title":"Trem2 acts as a tumor suppressor in hepatocellular carcinoma by targeting the pi3k\/akt\/beta-catenin pathway","volume":"8","author":"Tang","year":"2019","journal-title":"Oncogenesis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.05.003","article-title":"The physiology, pathology, and potential therapeutic applications of the trem2 signaling pathway","volume":"181","author":"Deczkowska","year":"2020","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1159\/000515909","article-title":"Long noncoding rna ttc39a-as1 promotes breast cancer tumorigenicity by sponging microrna-483-3p and thereby upregulating mta2","volume":"106","author":"Zhou","year":"2021","journal-title":"Pharmacology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216257","article-title":"Fbxw10-S6k1 promotes anxa2 polyubiquitination and kras activation to drive hepatocellular carcinoma development in males","volume":"566","author":"Liu","year":"2023","journal-title":"Cancer Lett"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2017.08.024","article-title":"Protein phosphorylation and its role in the regulation of annexin A2 function","volume":"1861","author":"Grindheim","year":"2017","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1915","article-title":"Mesenchymal stem cells promote hepatocarcinogenesis via lncrna-muf interaction with anxa2 and mir-34a","volume":"77","author":"Yan","year":"2017","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1303426","article-title":"Machine learning identifies ferroptosis-related gene anxa2 as potential diagnostic biomarkers for nafld","volume":"14","author":"Qin","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166413","article-title":"The annexin A2-notch regulatory loop in hepatocytes promotes liver fibrosis in nafld by increasing osteopontin expression","volume":"1868","author":"Wang","year":"2022","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41574-021-00529-7","article-title":"Gdf15: emerging biology and therapeutic applications for obesity and cardiometabolic disease","volume":"17","author":"Wang","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1053\/j.gastro.2020.12.015","article-title":"Hepatic stellate cells in hepatocellular carcinoma promote tumor growth via growth differentiation factor 15 production","volume":"160","author":"Myojin","year":"2021","journal-title":"Gastroenterology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/liv.13587","article-title":"Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease","volume":"38","author":"Koo","year":"2018","journal-title":"Liver Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1502263\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T05:10:46Z","timestamp":1733289046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1502263\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2024.1502263"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1502263","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"article-number":"1502263"}}